CA2378955A1 - Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy - Google Patents

Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy Download PDF

Info

Publication number
CA2378955A1
CA2378955A1 CA002378955A CA2378955A CA2378955A1 CA 2378955 A1 CA2378955 A1 CA 2378955A1 CA 002378955 A CA002378955 A CA 002378955A CA 2378955 A CA2378955 A CA 2378955A CA 2378955 A1 CA2378955 A1 CA 2378955A1
Authority
CA
Canada
Prior art keywords
compound
aminobutyramide
gamma
delivering
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378955A
Other languages
English (en)
French (fr)
Inventor
Jay M. Meythaler
Jean Peduzzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2378955A1 publication Critical patent/CA2378955A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002378955A 1999-08-10 2000-08-10 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy Abandoned CA2378955A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14815999P 1999-08-10 1999-08-10
US60/148,159 1999-08-10
PCT/US2000/021886 WO2001010432A1 (en) 1999-08-10 2000-08-10 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy

Publications (1)

Publication Number Publication Date
CA2378955A1 true CA2378955A1 (en) 2001-02-15

Family

ID=22524556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378955A Abandoned CA2378955A1 (en) 1999-08-10 2000-08-10 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy

Country Status (8)

Country Link
US (1) US20060142396A1 (enExample)
EP (1) EP1202720A4 (enExample)
JP (1) JP2003506407A (enExample)
AU (1) AU771115B2 (enExample)
CA (1) CA2378955A1 (enExample)
IL (1) IL148052A0 (enExample)
NZ (1) NZ517407A (enExample)
WO (1) WO2001010432A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6892098B2 (en) 2001-04-26 2005-05-10 Biocontrol Medical Ltd. Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
US6907295B2 (en) 2001-08-31 2005-06-14 Biocontrol Medical Ltd. Electrode assembly for nerve control
US7778711B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US7778703B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Selective nerve fiber stimulation for treating heart conditions
US7561922B2 (en) 2004-12-22 2009-07-14 Biocontrol Medical Ltd. Construction of electrode assembly for nerve control
US7321793B2 (en) 2003-06-13 2008-01-22 Biocontrol Medical Ltd. Vagal stimulation for atrial fibrillation therapy
US8880192B2 (en) 2012-04-02 2014-11-04 Bio Control Medical (B.C.M.) Ltd. Electrode cuffs
US7627384B2 (en) 2004-11-15 2009-12-01 Bio Control Medical (B.C.M.) Ltd. Techniques for nerve stimulation
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US7824697B2 (en) 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
WO2008066750A1 (en) * 2006-11-22 2008-06-05 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
US8969414B2 (en) * 2009-02-06 2015-03-03 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
US20150258279A1 (en) 2008-03-18 2015-09-17 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms and related delivery system
US8475823B2 (en) * 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
WO2010027266A1 (en) * 2008-09-05 2010-03-11 Van De Langenberg, Hendrikus Theodorus Ardina Hubertus Means and methods for counteracting neurological disorders
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US9186504B2 (en) 2010-11-15 2015-11-17 Rainbow Medical Ltd Sleep apnea treatment
US9457186B2 (en) 2010-11-15 2016-10-04 Bluewind Medical Ltd. Bilateral feedback
WO2013111137A2 (en) 2012-01-26 2013-08-01 Rainbow Medical Ltd. Wireless neurqstimulatqrs
WO2014087337A1 (en) 2012-12-06 2014-06-12 Bluewind Medical Ltd. Delivery of implantable neurostimulators
US9370660B2 (en) 2013-03-29 2016-06-21 Rainbow Medical Ltd. Independently-controlled bidirectional nerve stimulation
US10004896B2 (en) 2015-01-21 2018-06-26 Bluewind Medical Ltd. Anchors and implant devices
US9597521B2 (en) 2015-01-21 2017-03-21 Bluewind Medical Ltd. Transmitting coils for neurostimulation
US9764146B2 (en) 2015-01-21 2017-09-19 Bluewind Medical Ltd. Extracorporeal implant controllers
US9782589B2 (en) 2015-06-10 2017-10-10 Bluewind Medical Ltd. Implantable electrostimulator for improving blood flow
US10105540B2 (en) 2015-11-09 2018-10-23 Bluewind Medical Ltd. Optimization of application of current
US9713707B2 (en) 2015-11-12 2017-07-25 Bluewind Medical Ltd. Inhibition of implant migration
US10124178B2 (en) 2016-11-23 2018-11-13 Bluewind Medical Ltd. Implant and delivery tool therefor
US20180353764A1 (en) 2017-06-13 2018-12-13 Bluewind Medical Ltd. Antenna configuration
EP3542799A1 (en) * 2018-03-22 2019-09-25 Helsinn Healthcare SA New centrally-active ghrelin agonist and medical uses thereof
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2489319A1 (fr) * 1980-08-27 1982-03-05 Clin Midy Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant
IT1137492B (it) * 1981-05-26 1986-09-10 Maria Curti Composti ad attivita' gaba simile,procedimento per prepararli e composizioni farmaceutiche che li comprendono
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US5711316A (en) * 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US7354954B1 (en) * 2000-08-10 2008-04-08 Meythaler Jay M Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
DE602005020667D1 (de) * 2004-09-16 2010-05-27 Janssen Pharmaceutica Nv Verwendung von 2-phenyl-1,2-ethanediol-(di)carbamaten zur behandlung von epileptogenese

Also Published As

Publication number Publication date
EP1202720A4 (en) 2004-02-25
EP1202720A1 (en) 2002-05-08
IL148052A0 (en) 2002-09-12
AU6764500A (en) 2001-03-05
AU771115B2 (en) 2004-03-11
US20060142396A1 (en) 2006-06-29
WO2001010432A1 (en) 2001-02-15
JP2003506407A (ja) 2003-02-18
NZ517407A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
AU771115B2 (en) Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy
Ochs et al. Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.
Heetla et al. Clinical relevance of pharmacological and physiological data in intrathecal baclofen therapy
US6969383B2 (en) Method for treating severe tinnitus
US6656172B1 (en) Method for treating severe tinnitus
Lewis et al. Intrathecal baclofen for severe spasticity secondary to spinal cord injury
PT100850B (pt) Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas
US11285099B2 (en) Topical phenytoin for use in the treatment of peripheral neuropathic pain
US9655968B2 (en) Baclofen solution for low-volume therapeutic delivery
US20060160899A1 (en) Intrathecal Gabapentin for Treatment of Epilepsy
US7354954B1 (en) Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy
US20050004219A1 (en) Pump systems including injectable gabapentin compositions
Abraham et al. Intrathecal and intracerebroventricular dopamine for Parkinson’s disease
CA2389476C (en) Treatment of dyskinesia with a h3-histamine receptor agonist
Ethans Intrathecal baclofen therapy: indications, pharmacology, surgical implant, and efficacy
EP1735057A2 (en) Method and compositions for treatment of chronic neuropathic pain
MXPA02001368A (en) Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy
EP1210100B1 (en) Method of treating traumatic brain using non-steroidal anti-inflammatory drugs
Oommen et al. Intraventricular administration of gabapentin in the rat increases flurothyl seizure threshold
Heetla Pharmacokinetics and pharmacodynamics of intrathecal baclofen therapy
Barcia et al. Continuous intra-amygdalar infusion of GABA in the amygdala kindling model of epilepsy in rat
Campos et al. Pharmacology of intrathecal therapy
Krames et al. Future trends in the development of local drug delivery systems: intraspinal, intracerebral, and intraparenchymal therapies
Martin et al. Blood-Brain Barrier
Penn et al. The History and Evolution of Intrathecal Drug Delivery: From the 1950s to the Present

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued